IMAC vs. BEAT, CERS, MGTX, ANRO, LFMD, TNYA, SBTX, NAUT, SOPH, and ZYXI
Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include BioTelemetry (BEAT), Cerus (CERS), MeiraGTx (MGTX), Alto Neuroscience (ANRO), LifeMD (LFMD), Tenaya Therapeutics (TNYA), Silverback Therapeutics (SBTX), Nautilus Biotechnology (NAUT), SOPHiA GENETICS (SOPH), and Zynex (ZYXI). These companies are all part of the "medical" sector.
BioTelemetry (NASDAQ:BEAT) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.
BioTelemetry has a net margin of 0.00% compared to BioTelemetry's net margin of -75.40%. BioTelemetry's return on equity of -52.17% beat IMAC's return on equity.
7.8% of BioTelemetry shares are owned by institutional investors. Comparatively, 24.3% of IMAC shares are owned by institutional investors. 20.9% of BioTelemetry shares are owned by insiders. Comparatively, 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
BioTelemetry has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, IMAC has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500.
IMAC has higher revenue and earnings than BioTelemetry.
In the previous week, BioTelemetry had 1 more articles in the media than IMAC. MarketBeat recorded 2 mentions for BioTelemetry and 1 mentions for IMAC. BioTelemetry's average media sentiment score of 0.03 beat IMAC's score of 0.00 indicating that IMAC is being referred to more favorably in the news media.
BioTelemetry received 318 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 63.77% of users gave BioTelemetry an outperform vote while only 60.17% of users gave IMAC an outperform vote.
BioTelemetry presently has a consensus price target of $8.00, indicating a potential upside of 187.77%. Given IMAC's higher possible upside, equities research analysts plainly believe BioTelemetry is more favorable than IMAC.
Summary
BioTelemetry and IMAC tied by winning 7 of the 14 factors compared between the two stocks.
Get IMAC News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
